Literature DB >> 17339863

The pharmacogenetics research network: from SNP discovery to clinical drug response.

K M Giacomini1, C M Brett, R B Altman, N L Benowitz, M E Dolan, D A Flockhart, J A Johnson, D F Hayes, T Klein, R M Krauss, D L Kroetz, H L McLeod, A T Nguyen, M J Ratain, M V Relling, V Reus, D M Roden, C A Schaefer, A R Shuldiner, T Skaar, K Tantisira, R F Tyndale, L Wang, R M Weinshilboum, S T Weiss, I Zineh.   

Abstract

The NIH Pharmacogenetics Research Network (PGRN) is a collaborative group of investigators with a wide range of research interests, but all attempting to correlate drug response with genetic variation. Several research groups concentrate on drugs used to treat specific medical disorders (asthma, depression, cardiovascular disease, addiction of nicotine, and cancer), whereas others are focused on specific groups of proteins that interact with drugs (membrane transporters and phase II drug-metabolizing enzymes). The diverse scientific information is stored and annotated in a publicly accessible knowledge base, the Pharmacogenetics and Pharmacogenomics Knowledge base (PharmGKB). This report highlights selected achievements and scientific approaches as well as hypotheses about future directions of each of the groups within the PGRN. Seven major topics are included: informatics (PharmGKB), cardiovascular, pulmonary, addiction, cancer, transport, and metabolism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339863      PMCID: PMC5006950          DOI: 10.1038/sj.clpt.6100087

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  102 in total

Review 1.  Heterogeneity of therapeutic responses in asthma.

Authors:  J M Drazen; E K Silverman; T H Lee
Journal:  Br Med Bull       Date:  2000       Impact factor: 4.291

2.  Natural variation in human membrane transporter genes reveals evolutionary and functional constraints.

Authors:  Maya K Leabman; Conrad C Huang; Joseph DeYoung; Elaine J Carlson; Travis R Taylor; Melanie de la Cruz; Susan J Johns; Doug Stryke; Michiko Kawamoto; Thomas J Urban; Deanna L Kroetz; Thomas E Ferrin; Andrew G Clark; Neil Risch; Ira Herskowitz; Kathleen M Giacomini
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-28       Impact factor: 11.205

3.  Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension.

Authors:  Amber L Beitelshees; Issam Zineh; Hossein N Yarandi; Daniel F Pauly; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2006-09       Impact factor: 4.705

4.  Polymorphism screening in the cardiac K+ channel gene KCNA5.

Authors:  Chantale Simard; Benoit Drolet; Ping Yang; Richard B Kim; Dan M Roden
Journal:  Clin Pharmacol Ther       Date:  2005-03       Impact factor: 6.875

Review 5.  Overview of the pharmacogenetics of asthma treatment.

Authors:  S T Weiss; A A Litonjua; C Lange; R Lazarus; S B Liggett; E R Bleecker; K G Tantisira
Journal:  Pharmacogenomics J       Date:  2006-04-25       Impact factor: 3.550

6.  Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia.

Authors:  Sanne Lugthart; Meyling H Cheok; Monique L den Boer; Wenjian Yang; Amy Holleman; Cheng Cheng; Ching-Hon Pui; Mary V Relling; Gritta E Janka-Schaub; Rob Pieters; William E Evans
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

7.  Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.

Authors:  Young Chai Lim; Lang Li; Zeruesenay Desta; Qianqian Zhao; James M Rae; David A Flockhart; Todd C Skaar
Journal:  J Pharmacol Exp Ther       Date:  2006-05-11       Impact factor: 4.030

8.  Increased atrial fibrillation mortality: United States, 1980-1998.

Authors:  Wendy A Wattigney; George A Mensah; Janet B Croft
Journal:  Am J Epidemiol       Date:  2002-05-01       Impact factor: 4.897

9.  Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.

Authors:  Deanna L Kroetz; Christiane Pauli-Magnus; Laura M Hodges; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Doug Stryke; Thomas E Ferrin; Joseph DeYoung; Travis Taylor; Elaine J Carlson; Ira Herskowitz; Kathleen M Giacomini; Andrew G Clark
Journal:  Pharmacogenetics       Date:  2003-08

10.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.

Authors:  Patricia A Gum; Kandice Kottke-Marchant; Patricia A Welsh; Jennifer White; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

View more
  74 in total

1.  Clinical and translational sciences: at the intersection of molecular and individualized medicine.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2008-05       Impact factor: 4.689

2.  Experimental therapeutics: a paradigm for personalized medicine.

Authors:  Scott A Waldman; Walter K Kraft; Timothy J Nelson; Andre Terzic
Journal:  Clin Transl Sci       Date:  2009-12       Impact factor: 4.689

3.  Knowledge of Pharmacogenetics among Healthcare Professionals and Faculty Members of Health Training Institutions in Ghana.

Authors:  W Kudzi; B S Addy; B Dzudzor
Journal:  Ghana Med J       Date:  2015-03

4.  Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.

Authors:  Wei Zhang; R Stephanie Huang; M Eileen Dolan
Journal:  Trends Cancer Res       Date:  2008

Review 5.  K(ATP) channel pharmacogenomics: from bench to bedside.

Authors:  S Sattiraju; S Reyes; G C Kane; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2007-10-24       Impact factor: 6.875

6.  Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations.

Authors:  Ningwu Huang; Vishal Agrawal; Kathleen M Giacomini; Walter L Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

Review 7.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

8.  Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society.

Authors:  Vural Ozdemir; Guilherme Suarez-Kurtz; Raphaëlle Stenne; Andrew A Somogyi; Toshiyuki Someya; S Oğuz Kayaalp; Eugene Kolker
Journal:  OMICS       Date:  2009-02

9.  PharmGKB: an integrated resource of pharmacogenomic data and knowledge.

Authors:  Li Gong; Ryan P Owen; Winston Gor; Russ B Altman; Teri E Klein
Journal:  Curr Protoc Bioinformatics       Date:  2008-09

10.  Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5).

Authors:  Harunobu Tahara; Sook Wah Yee; Thomas J Urban; Stephanie Hesselson; Richard A Castro; Michiko Kawamoto; Doug Stryke; Susan J Johns; Thomas E Ferrin; Pui-Yan Kwok; Kathleen M Giacomini
Journal:  J Pharmacol Exp Ther       Date:  2009-01-13       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.